Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials
Galectins are small proteins with pleiotropic functions, which depend on both their lectin (glycan recognition) and non-lectin (recognition of other biomolecules besides glycans) interactions. Currently, 15 members of this family have been described in mammals, each with its structural and ligand re...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/5/750 |
| _version_ | 1797568253962223616 |
|---|---|
| author | Daniel Compagno Carolina Tiraboschi José Daniel Garcia Yorfer Rondón Enrique Corapi Carla Velazquez Diego José Laderach |
| author_facet | Daniel Compagno Carolina Tiraboschi José Daniel Garcia Yorfer Rondón Enrique Corapi Carla Velazquez Diego José Laderach |
| author_sort | Daniel Compagno |
| collection | DOAJ |
| description | Galectins are small proteins with pleiotropic functions, which depend on both their lectin (glycan recognition) and non-lectin (recognition of other biomolecules besides glycans) interactions. Currently, 15 members of this family have been described in mammals, each with its structural and ligand recognition particularities. The galectin/ligand interaction translates into a plethora of biological functions that are particular for each cell/tissue type. In this sense, the cells of the immune system are highly sensitive to the action of these small and essential proteins. While galectins play central roles in tumor progression, they are also excellent negative regulators (checkpoints) of the immune cell functions, participating in the creation of a microenvironment that promotes tumor escape. This review aims to give an updated view on how galectins control the tumor’s immune attack depending on the tumor microenvironment, because determining which galectins are essential and the role they play will help to develop future clinical trials and benefit patients with incurable cancer. |
| first_indexed | 2024-03-10T19:53:49Z |
| format | Article |
| id | doaj.art-b195a4ca5a554678840d5600faf277d6 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T19:53:49Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-b195a4ca5a554678840d5600faf277d62023-11-20T00:08:37ZengMDPI AGBiomolecules2218-273X2020-05-0110575010.3390/biom10050750Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical TrialsDaniel Compagno0Carolina Tiraboschi1José Daniel Garcia2Yorfer Rondón3Enrique Corapi4Carla Velazquez5Diego José Laderach6Molecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaMolecular and Functional Glyco-Oncology Laboratory, IQUIBICEN-CONICET-UBA, Ciudad Autónoma de Buenos Aires C1428EGA, ArgentinaGalectins are small proteins with pleiotropic functions, which depend on both their lectin (glycan recognition) and non-lectin (recognition of other biomolecules besides glycans) interactions. Currently, 15 members of this family have been described in mammals, each with its structural and ligand recognition particularities. The galectin/ligand interaction translates into a plethora of biological functions that are particular for each cell/tissue type. In this sense, the cells of the immune system are highly sensitive to the action of these small and essential proteins. While galectins play central roles in tumor progression, they are also excellent negative regulators (checkpoints) of the immune cell functions, participating in the creation of a microenvironment that promotes tumor escape. This review aims to give an updated view on how galectins control the tumor’s immune attack depending on the tumor microenvironment, because determining which galectins are essential and the role they play will help to develop future clinical trials and benefit patients with incurable cancer.https://www.mdpi.com/2218-273X/10/5/750galectinscarbohydratesgalectin |
| spellingShingle | Daniel Compagno Carolina Tiraboschi José Daniel Garcia Yorfer Rondón Enrique Corapi Carla Velazquez Diego José Laderach Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials Biomolecules galectins carbohydrates galectin |
| title | Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials |
| title_full | Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials |
| title_fullStr | Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials |
| title_full_unstemmed | Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials |
| title_short | Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials |
| title_sort | galectins as checkpoints of the immune system in cancers their clinical relevance and implication in clinical trials |
| topic | galectins carbohydrates galectin |
| url | https://www.mdpi.com/2218-273X/10/5/750 |
| work_keys_str_mv | AT danielcompagno galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT carolinatiraboschi galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT josedanielgarcia galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT yorferrondon galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT enriquecorapi galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT carlavelazquez galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials AT diegojoseladerach galectinsascheckpointsoftheimmunesystemincancerstheirclinicalrelevanceandimplicationinclinicaltrials |